Deciphering the quality of SARS‐CoV‐2 specific T‐cell response associated with disease severity, immune memory and heterologous response
Abstract SARS‐CoV‐2 specific T‐cell response has been associated with disease severity, immune memory and heterologous response to endemic coronaviruses. However, an integrative approach combining a comprehensive analysis of the quality of SARS‐CoV‐2 specific T‐cell response with antibody levels in these three scenarios is needed. In the present study, we found that, in acute infection, while mild disease was associated with high T‐cell polyfunctionality biased to IL‐2 production and inversely correlated with anti‐S IgG levels, combinations only including IFN‐γ with the absence of perforin production predominated in severe disease. Seven months after infection, both non‐hospitalised and previously hospitalised patients presented robust anti‐S IgG levels and SARS‐CoV‐2 specific T‐cell response. In addition, only previously hospitalised patients showed a T‐cell exhaustion profile. Finally, combinations including IL‐2 in response to S protein of endemic coronaviruses were the ones associated with SARS‐CoV‐2 S‐specific T‐cell response in pre‐COVID‐19 healthy donors’ samples. These results could have implications for protective immunity against SARS‐CoV‐2 and recurrent COVID‐19 and may help for the design of new prototypes and boosting vaccine strategies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical and Translational Medicine - 12(2022), 4 |
| Beteiligte Personen: |
Pérez‐Gómez, Alberto [VerfasserIn] |
|---|
| Anmerkungen: |
© 2022 |
|---|
| Umfang: |
21 |
|---|
| doi: |
10.1002/ctm2.802 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004381211 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004381211 | ||
| 003 | DE-627 | ||
| 005 | 20230307135322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ctm2.802 |2 doi | |
| 028 | 5 | 2 | |a CTM2_CTM2802.xml |
| 035 | |a (DE-627)WLY004381211 | ||
| 035 | |a (WILEY)CTM2802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Pérez‐Gómez, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deciphering the quality of SARS‐CoV‐2 specific T‐cell response associated with disease severity, immune memory and heterologous response |
| 264 | 1 | |c 2022 | |
| 300 | |a 21 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 | ||
| 520 | |a Abstract SARS‐CoV‐2 specific T‐cell response has been associated with disease severity, immune memory and heterologous response to endemic coronaviruses. However, an integrative approach combining a comprehensive analysis of the quality of SARS‐CoV‐2 specific T‐cell response with antibody levels in these three scenarios is needed. In the present study, we found that, in acute infection, while mild disease was associated with high T‐cell polyfunctionality biased to IL‐2 production and inversely correlated with anti‐S IgG levels, combinations only including IFN‐γ with the absence of perforin production predominated in severe disease. Seven months after infection, both non‐hospitalised and previously hospitalised patients presented robust anti‐S IgG levels and SARS‐CoV‐2 specific T‐cell response. In addition, only previously hospitalised patients showed a T‐cell exhaustion profile. Finally, combinations including IL‐2 in response to S protein of endemic coronaviruses were the ones associated with SARS‐CoV‐2 S‐specific T‐cell response in pre‐COVID‐19 healthy donors’ samples. These results could have implications for protective immunity against SARS‐CoV‐2 and recurrent COVID‐19 and may help for the design of new prototypes and boosting vaccine strategies. | ||
| 700 | 1 | |a Gasca‐Capote, Carmen |4 aut | |
| 700 | 1 | |a Vitallé, Joana |4 aut | |
| 700 | 1 | |a Ostos, Francisco J. |4 aut | |
| 700 | 1 | |a Serna‐Gallego, Ana |4 aut | |
| 700 | 1 | |a Trujillo‐Rodríguez, María |4 aut | |
| 700 | 1 | |a Muñoz‐Muela, Esperanza |4 aut | |
| 700 | 1 | |a Giráldez‐Pérez, Teresa |4 aut | |
| 700 | 1 | |a Praena‐Segovia, Julia |4 aut | |
| 700 | 1 | |a Navarro‐Amuedo, María D. |4 aut | |
| 700 | 1 | |a Paniagua‐García, María |4 aut | |
| 700 | 1 | |a García‐Gutiérrez, Manuel |4 aut | |
| 700 | 1 | |a Aguilar‐Guisado, Manuela |4 aut | |
| 700 | 1 | |a Rivas‐Jeremías, Inmaculada |4 aut | |
| 700 | 1 | |a Jiménez‐León, María Reyes |4 aut | |
| 700 | 1 | |a Bachiller, Sara |4 aut | |
| 700 | 1 | |a Fernández‐Villar, Alberto |4 aut | |
| 700 | 1 | |a Pérez‐González, Alexandre |4 aut | |
| 700 | 1 | |a Gutiérrez‐Valencia, Alicia |4 aut | |
| 700 | 1 | |a Rafii‐El‐Idrissi Benhnia, Mohammed |4 aut | |
| 700 | 1 | |a Weiskopf, Daniela |4 aut | |
| 700 | 1 | |a Sette, Alessandro |4 aut | |
| 700 | 1 | |a López‐Cortés, Luis F. |4 aut | |
| 700 | 1 | |a Poveda, Eva |4 aut | |
| 700 | 1 | |a Ruiz‐Mateos, Ezequiel |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and Translational Medicine |g 12(2022), 4 |w (DE-627)WLY00437052X |x 20011326 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:4 |g extent:21 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 4 |g 21 | ||